TransMedics GroupTMDX +0.74%69 EPS without NRI is $4.38 as of Mar. 2026. GuruFocus rates TMDX with a GF Score™ of 69/100 and a GF Value™ of $168.19 (Possible Value Trap). The stock has 9 warning signs investors should review. Among 662 Medical Devices & Instruments companies, TransMedics Group ranks worse than 151057.25% on this metric.
TransMedics Group's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was $0.20.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $4.38.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for TransMedics Group's EPS without NRI or its related term are showing as below:
TMDX's 3-Year EPS without NRI Growth Rate is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 8.15 * Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TransMedics Group's EPS (Basic) for the
three
months ended in Mar. 2026 was $0.21.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $5.03.
TransMedics Group (NAS:TMDX) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
TransMedics Group EPS without NRI Related Terms
TransMedics Group EPS without NRI Historical Data
* Premium members only.
The historical data trend for TransMedics Group's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TMDX vs AXGN, BFLY, ESTA: EPS without NRI Comparison
For the Medical Devices subindustry, TransMedics Group's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TransMedics Group PE Ratio without NRI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, TransMedics Group's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where TransMedics Group's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.38
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TransMedics Group (TMDX) has a EPS without NRI of $4.38 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on TransMedics Group and its competitors. According to the industry distribution chart, TransMedics Group ranks #999999 out of 662 companies in the Medical Devices & Instruments industry.
Is TransMedics Group's EPS without NRI too high?
TransMedics Group's current EPS without NRI is $4.38. The Medical Devices & Instruments industry median EPS without NRI is 8.15. TransMedics Group's value of $4.38 is 46.3% below this industry median. Based on the distribution chart, TransMedics Group ranks #999999 out of 662 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, TransMedics Group has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TransMedics Group's EPS without NRI compare to AXGN and BFLY?
According to the Medical Devices & Instruments industry distribution chart, TransMedics Group ranks #999999 out of 662 companies for EPS without NRI. This places TransMedics Group in the lower half of its industry. The industry median EPS without NRI is 8.15. TransMedics Group's value of $4.38 is 46.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Devices & Instruments company?
The median EPS without NRI among Medical Devices & Instruments companies is 8.15, based on 662 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TransMedics Group's current EPS without NRI of $4.38 is 46.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on TransMedics Group and its competitors. For the Medical Devices & Instruments industry, the median EPS without NRI is 8.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TransMedics Group's current EPS without NRI is $4.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransMedics Group stock overvalued right now?
Based on GuruFocus' analysis, TransMedics Group (TMDX) is currently considered Possible Value Trap. The stock's GF Value™ is $168.19, compared to a current price of $70.96 — trading 57.8% below its estimated fair value. The current EPS without NRI is $4.38 and 46.3% below the Medical Devices & Instruments industry median of 8.15. TransMedics Group's overall GF Score™ is 69/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For TransMedics Group (TMDX), the current EPS without NRI is $4.38 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TransMedics Group (TMDX) Overvalued in 2026?
Based on GuruFocus' analysis, TransMedics Group stock appears to be undervalued.
The current stock price of $70.96 is trading 57.8% below its estimated GF Value™ of $168.19.
GuruFocus considers TransMedics Group to be Possible Value Trap.
Key valuation signals for TMDX:
EPS without NRI: $4.38
GF Value™: $168.19 vs. price of $70.96 (57.8% below fair value)
Industry Position: 46.3% below the Medical Devices & Instruments median (#999999 of 662)
No single metric tells the full story. See the TMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
69GF Score
Get the complete analysis for TMDX
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TMDX has been successfully added to your 
